Friday, December 2, 2011

First whole-genome sequencing clinical trials for triple-negative breast cancer presented

First whole-genome sequencing clinical trials for triple-negative breast cancer presented [ Back to EurekAlert! ] Public release date: 1-Dec-2011
[ | E-mail | Share Share ]

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Sequencing points to treatment protocols, results in patient benefit

CARLSBAD, Calif., DALLAS, PHOENIX, and THE WOODLANDS, Texas December 1, 2011 Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin (trastuzumab).

To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010, and the first results will be presented during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, Dec. 6-10, 2011.

Based on mutations uncovered by sequencing, physicians steered the women into treatment protocols for either existing drugs or new agents being evaluated in pharma-sponsored clinical trials. Several patients displayed benefit from treatments physicians selected taking sequencing data into consideration.

Results will be presented at 10:30 am CST, Thursday, Dec. 8, by Joyce O'Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research; a practicing oncologist with Texas Oncology; and the Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center.

The study, titled "Next Generation Sequencing Reveals Co-Activating Events in the MAPK and PI3K/AKT Pathways in Metastatic Triple Negative Breast Cancers," is sponsored by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life Technologies Corporation (NASDAQ:LIFE - News).

###

About Baylor Health Care System

Baylor Health Care System is a not-for-profit, faith-based supporting organization providing services to a network of acute care hospitals and related health care entities that provide patient care, medical education, research and community service. Baylor recorded more than 2.6 million patient encounters, $3.8 billion in total operating revenue, $4.4 billion in total assets and $513.5 million in community benefit in fiscal year 2010. Baylor's network of more than 300 access points includes 27 owned/operated/ ventured/affiliated hospitals, 23 joint ventured ambulatory surgical centers, 50 satellite outpatient locations, four senior centers and 156 HealthTexas Provider Network physician clinics.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

About Texas Oncology

Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve "More breakthroughs. More victories." in their fights against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas and southeastern Oklahoma. Texas Breast Specialists and Texas Urology Specialists, which focus on all areas of breast and urologic care, are a part of Texas Oncology.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Texas Oncology participates in innovative clinical trials from Phase I through Phase IV through US Oncology Research, which has helped to develop 43 FDA approved cancer therapies.

Texas Oncology is united in healing with The US Oncology Network, one of the nation's largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Texas Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. The US Oncology Network is supported by McKesson Specialty Health.

For more information, visit www.TexasOncology.com or call 1-888-864-I CAN (4226).

About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research for life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.

About US Oncology Research

McKesson Specialty Health conducts clinical trials through US Oncology Research, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.

Contacts:

Baylor Health Care System
Chris Callahan
Sr. Marketing and PR Consultant
(214) 820-6994 (Direct)
(214) 820-3055 (Office)
chris.callahan@baylorhealth.edu

Life Technologies
Suzanne Clancy
Senior Manager, Public Relations for Regulated Markets
760-602-4545
760-717-8294 (mobile)
suzanne.clancy@lifetech.com

Translational Genomics Research Institute
Steve Yozwiak
Senior Science Writer
602-343-8704
syozwiak@tgen.org

US Oncology Research and Texas Oncology
Claire Crye
281-863-6783
281-825-9927
claire.crye@mckesson.com


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


First whole-genome sequencing clinical trials for triple-negative breast cancer presented [ Back to EurekAlert! ] Public release date: 1-Dec-2011
[ | E-mail | Share Share ]

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Sequencing points to treatment protocols, results in patient benefit

CARLSBAD, Calif., DALLAS, PHOENIX, and THE WOODLANDS, Texas December 1, 2011 Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin (trastuzumab).

To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010, and the first results will be presented during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, Dec. 6-10, 2011.

Based on mutations uncovered by sequencing, physicians steered the women into treatment protocols for either existing drugs or new agents being evaluated in pharma-sponsored clinical trials. Several patients displayed benefit from treatments physicians selected taking sequencing data into consideration.

Results will be presented at 10:30 am CST, Thursday, Dec. 8, by Joyce O'Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research; a practicing oncologist with Texas Oncology; and the Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center.

The study, titled "Next Generation Sequencing Reveals Co-Activating Events in the MAPK and PI3K/AKT Pathways in Metastatic Triple Negative Breast Cancers," is sponsored by the Translational Genomics Research Institute (TGen) and US Oncology Research with support from Life Technologies Corporation (NASDAQ:LIFE - News).

###

About Baylor Health Care System

Baylor Health Care System is a not-for-profit, faith-based supporting organization providing services to a network of acute care hospitals and related health care entities that provide patient care, medical education, research and community service. Baylor recorded more than 2.6 million patient encounters, $3.8 billion in total operating revenue, $4.4 billion in total assets and $513.5 million in community benefit in fiscal year 2010. Baylor's network of more than 300 access points includes 27 owned/operated/ ventured/affiliated hospitals, 23 joint ventured ambulatory surgical centers, 50 satellite outpatient locations, four senior centers and 156 HealthTexas Provider Network physician clinics.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

About Texas Oncology

Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve "More breakthroughs. More victories." in their fights against cancer. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas and southeastern Oklahoma. Texas Breast Specialists and Texas Urology Specialists, which focus on all areas of breast and urologic care, are a part of Texas Oncology.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Texas Oncology participates in innovative clinical trials from Phase I through Phase IV through US Oncology Research, which has helped to develop 43 FDA approved cancer therapies.

Texas Oncology is united in healing with The US Oncology Network, one of the nation's largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Texas Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. The US Oncology Network is supported by McKesson Specialty Health.

For more information, visit www.TexasOncology.com or call 1-888-864-I CAN (4226).

About TGen

The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research for life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.

About US Oncology Research

McKesson Specialty Health conducts clinical trials through US Oncology Research, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.

Contacts:

Baylor Health Care System
Chris Callahan
Sr. Marketing and PR Consultant
(214) 820-6994 (Direct)
(214) 820-3055 (Office)
chris.callahan@baylorhealth.edu

Life Technologies
Suzanne Clancy
Senior Manager, Public Relations for Regulated Markets
760-602-4545
760-717-8294 (mobile)
suzanne.clancy@lifetech.com

Translational Genomics Research Institute
Steve Yozwiak
Senior Science Writer
602-343-8704
syozwiak@tgen.org

US Oncology Research and Texas Oncology
Claire Crye
281-863-6783
281-825-9927
claire.crye@mckesson.com


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2011-12/ttgr-fws113011.php

uekman music awards music awards giants eagles bcs rankings week 13 bcs rankings week 13 philadelphia marathon

Thursday, December 1, 2011

Video: Current Deal-Making Environment

Insight on the impact of Europe's sovereign debt crisis and the current gridlock in Washington on the deal-making environment.Stephen Pagliuca, Bain Capital managing director.

Related Links:

Business & financial news headlines from msnbc.com

Source: http://video.msnbc.msn.com/cnbc/45508650/

frances bean cobain bill gates michael lewis palin occupy wall street second time around bill gates steve jobs

Sarkozy: Paris, Berlin to push for treaty changes (AP)

PARIS ? French President Nicolas Sarkozy says he and the German chancellor will push for European treaty changes to "rethink the organization of Europe" in order to protect the euro.

Sarkozy said in a speech on Thursday that he and Angela Merkel would unveil proposals at a meeting on Monday in Paris.

But he provided few details about what the changes would entail.

THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP's earlier story is below.

PARIS (AP) ? French President Nicolas Sarkozy says he and the German chancellor will meet in Paris on Monday to unveil proposals that he said will "guarantee the future of Europe."

Sarkozy, who was speaking in Toulon in southern France on Thursday, did not specify what he and Angela Merkel might propose to help alleviate Europe's financial crisis.

The two countries are the powerhouses of the European economy.

Source: http://us.rd.yahoo.com/dailynews/rss/business/*http%3A//news.yahoo.com/s/ap/20111201/ap_on_bi_ge/eu_france_financial_crisis

love and hip hop dancing with the stars results there will be blood

Republicans aim to quash new union rules (AP)

WASHINGTON ? Republicans are maneuvering to short-circuit an effort by Democrats on the National Labor Relations Board to approve rules that would quicken the pace of union elections.

The GOP member of the labor board is threatening to resign his post, which would deny the board a quorum and quash the entire process. At the same time, the House is poised Wednesday to approve a GOP bill aimed at short-circuiting moves they consider anti-business. That measure is unlikely to go anywhere in the Senate.

The developments are the latest sign of how intensely business groups are opposing any moves that could help organized labor make new inroads at companies that have long opposed unions.

At the labor board, the Democratic majority was set to take up a proposal Wednesday that would simplify procedures and shorten deadlines for holding union elections after employees at a work site gather enough signatures.

But the board's lone GOP member, Brian Hayes, has threatened to quit the agency over his objection to the planned rules, an unprecedented move that would render the board powerless to approve any new measures at all. The board needs at least three members to make any decisions.

If Hayes leaves, only two members ? both Democrats ? would remain instead of the five members it's supposed to have. Congressional Republicans have blocked President Barack Obama from filling the other two vacancies at the board.

Under current rules, union elections typically take place within 45-60 days after a union gathers enough signatures to file a petition. Republicans contend the new rules could shorten that time to as little as 10 days.

Unions claim companies often abuse current rules to file frivolous appeals, holding up elections for months or even years. But business groups claim the plan would give unions "quickie" elections without leaving employers enough time to respond.

The board's majority has been rushing to approve the new rules before the end of the year, when the term of one of the two Democratic members expires. A modified plan being considered Wednesday is a limited version of more sweeping rules proposed earlier this year. It would not, for example, require employers to provide a list of worker phone numbers and email addresses in voter lists provided to unions.

A final vote on the rules would take place next month, unless Hayes leaves the board.

Hayes has vowed not to participate at the Wednesday meeting and threatened to resign his post over his objection to the rules, according to a letter from the board's chairman, Mark Pearce, circulated last week. Hayes has declined requests for comment.

Union officials have decried Hayes' threat as a bullying tactic that undermines the board.

"We are shocked by the idea that a partisan difference would shut down the workings of a federal agency," said Peter Colavito, director of government relations for the Service Employees International Union.

Minnesota Rep. John Kline, GOP chairman of the House Committee on Education and the Workforce, blamed the board's Democratic majority and called on Pearce to withdraw "his ambush election proposal."

The bitter feud between Hayes and the board's two Democrats is the latest sign of how polarizing the debate over union rights has become. Board members often quarrel over policy differences, depending on which political party is in the majority. But labor experts say a board member has never resigned for the sole purpose of preventing a vote.

"As far as I'm aware, it's unprecedented," said William Gould, a former NLRB chairman during the Clinton administration and now a professor at Stanford Law School. "The board has become more polarized, but this takes it to a different level entirely."

In the House, meanwhile, Republicans are expected to pass a bill that would override any changes to NLRB election rules. The measure would delay any vote on a union for at least 35 days after a petition is filed.

The bill would also overturn a recent board ruling that made it easier for smaller groups of workers within companies to organize bargaining units. Business groups claim so-called "micro-bargaining unions" would allow unions to cherry-pick certain departments or employees within a company.

"Congress must act now to thwart the NLRB's radical regulatory maneuvers," said David French, a vice president for government relations at the National Retail Federation, the world's largest retail trade group.

The federation, whose members include J.C. Penney, Best Buy Co. and Macy's Inc., claims the board's proposed rules would limit workers access to "information needed to make an informed decision about union representation."

California Rep. George Miller, top Democrat on the House Education and the Workforce committee, has denounced the measure as an "anti-worker, anti-family bill" that would undermine worker rights.

The bill is not expected to go far in the Senate, where Democratic leaders are not likely to bring it to a vote.

___

Follow Sam Hananel on Twitter at http://twitter.com/shananel

Source: http://us.rd.yahoo.com/dailynews/rss/gop/*http%3A//news.yahoo.com/s/ap/20111130/ap_on_go_co/us_unions_elections

ambition dorothy rodham rick hendrick plane crash marco rubio marco rubio no shave november kevin durant

Meeting with wife may be key to future of Cain bid (AP)

MANCHESTER, N.H. ? He's plotting an aggressive campaign schedule across several states, but Herman Cain has begun to outline a possible exit strategy from the race for the Republican presidential nomination.

The former business executive, facing a woman's allegation of a 13-year extramarital affair, says a heavy emotional toll on his family ? particularly his wife, Gloria, who he has not seen since the charge surfaced ? could force him to call it quits. The shift comes as a growing chorus of would-be allies suggests he is no longer a viable presidential contender and Cain himself says fundraising has suffered.

Cain, a top-tier candidate just weeks ago, says he'll decide in the next "few days" whether to abandon his White House bid, but not before he meets with his wife.

"Since I've been campaigning all week, I haven't had an opportunity to sit down with her and walk through this with my wife and my family. I will do that when I get back home on Friday," Cain told reporters gathered at his New Hampshire campaign headquarters Wednesday night. "I am not going to make a decision until after we talk face to face."

Cain said he had spoken to his wife only by phone since Monday, the day an Atlanta television station reported the woman's accusation. Since then, aides have crafted a packed campaign schedule with stops in Ohio, New Hampshire, Tennessee, South Carolina and Georgia and prepared to launch a fresh round of TV ads in Iowa.

Cain was to sit down Thursday afternoon with the New Hampshire Union Leader, an influential conservative voice in the first-in-the-nation primary state. This evening the former pizza executive is scheduled to deliver a business-focused speech at Middle Tennessee State University.

"There were some people who thought that I was finished," Cain said Wednesday night. "But I'm going to leave it with Yogi Berra's comment: `It ain't over till it's over.' And it ain't over yet."

Many Republican operatives believe Cain's bid is over whether he pulls the plug or not.

"I don't see how they walk away from the damage that's been done and emerge as a viable primary candidate," said Rick Wilson, a longtime GOP consultant based in Florida. "All these things about Herman Cain keep coming out drip, drip, drip, and they're not handling it well. And now conservative Republicans have another place to go: Newt Gingrich."

Dan McLagan, a veteran GOP strategist based in Atlanta, said Cain "is like a zombie at this point: He's dead but he does not appear to have noticed and has kept on walking."

"His support is all moving to Gingrich and, at some point, he's going to look back and see that he is grand marshal of a one-man parade," McLagan said.

Gingrich has been the beneficiary ? in polls, at least ? of Cain's slide in the month since it was disclosed that the National Restaurant Association paid settlements to two women who claimed Cain sexually harassed them while he was its president. A third woman told The Associated Press that Cain made inappropriate sexual advances but that she didn't file a complaint. A fourth woman also stepped forward to accuse Cain of groping her in a car in 1997.

Cain has denied wrongdoing in all cases.

Atlanta-area businesswoman Ginger White, 46, said her affair with Cain ended this year before he became a White House candidate. He has denied any such affair, and in a letter addressed to "patriots and supporters" called her allegations "completely false" and labeled her "troubled."

"It's very disappointing that he would call me troubled and, you know, it's unfortunate," White said Wednesday on ABC's "Good Morning America."

Top aides huddled privately Wednesday to map out a strategy to get past the allegations. He has told his top supporters that his campaign must determine whether he will have the financial and grassroots support to move ahead.

"The day that this latest one hit, fundraising went way down," Cain told reporters in New Hampshire. "As the week has gone on and this woman who has made these accusations has basically started to contradict herself, our fundraising has started to go back up. It's not up to the level where it was, but a lot of people are saying, you know what, they don't believe it."

In New Hampshire and at other campaign stops this week, he renewed what has become a familiar defense: that he is the victim of attacks by liberals and the establishment, who are threatened by his outsider appeal.

"They want you to believe that with another character assassination on me that I will drop out," a defiant Cain told a crowd of about 200 Wednesday in Dayton, Ohio. Some responded with shouts of "No!" and "Boo!"

In Iowa, Cain's state chairman, Steve Grubbs, said he was preparing a busy December schedule beginning with a Dec. 10 debate in Des Moines. And Grubbs said Cain, who has not aired any campaign ads in Iowa since last week, will resume advertising Friday with a new spot that asserts that electing Cain would put a veteran CEO in the White House, not a politician.

"His campaign is strong enough to survive the allegations," said Michael Farren, 31, an Ohio State University doctoral student in economics, from Pataskala, Ohio.

___

Associated Press writers Shannon McCaffrey in Atlanta, Ann Sanner in Columbus, Ohio, Tom Beaumont in Des Moines, Iowa, and Kasie Hunt in New York contributed to this report.

Source: http://us.rd.yahoo.com/dailynews/rss/topstories/*http%3A//news.yahoo.com/s/ap/20111201/ap_on_el_pr/us_cain

snow white and the huntsman trailer snow white and the huntsman trailer sexiest man alive kentucky basketball heather locklear bob costas krzyzewski

Top Marine says service embracing gay ban repeal (AP)

MANAMA, Bahrain ? Since the lifting two months ago of a longstanding U.S. ban on gays serving openly in the military, U.S. Marines across the globe have adapted smoothly and embraced the change, says their top officer, Gen. James F. Amos, who previously had argued against repealing the ban during wartime.

"I'm very pleased with how it has gone," Amos said in an Associated Press interview during a week-long trip that included four days in Afghanistan, where he held more than a dozen town hall-style meetings with Marines of virtually every rank. He was asked about a wide range of issues, from his view of the Marine Corps' future to more mundane matters such as why he recently decided to stop allowing Marines to wear their uniform with the sleeves rolled up.

Not once was he asked in Afghanistan about the repeal of the gay ban.

Nor did it come up when he fielded questions from Marines on board the USS Bataan warship in the Gulf of Aden on Saturday. On his final stop, in Bahrain on Sunday, one Marine broached the topic gently. He asked Amos whether he planned to change the Marines' current policy of leaving it to the discretion of local commanders to determine how to handle complaints about derogatory "homosexual remarks or actions." Amos said no.

The apparent absence of angst about gays serving openly in the Marines seemed to confirm Amos' view that the change has been taken in stride, without hurting the war effort.

In the AP interview, he offered an anecdote to make his point. He said that at the annual ball in Washington earlier this month celebrating the birth of the Marine Corps, a female Marine approached Amos's wife, Bonnie, and introduced herself and her lesbian partner.

"Bonnie just looked at them and said, `Happy birthday ball. This is great. Nice to meet you,'" Amos said. "That is happening throughout the Marine Corps."

Amos said he is aware of only one reported incident in Afghanistan thus far, and that turned out to be a false alarm. He said a blogger had written of a gay Marine being harassed by fellow Marines for his sexual orientation. In an ensuing investigation, the gay Marine denied he had been harassed.

A Defense Department spokeswoman, Cynthia O. Smith, said implementation of the repeal of the gay ban is proceeding smoothly across the military.

"We attribute this success to our comprehensive pre-repeal training program, combined with the continued close monitoring and enforcement of standards by our military leaders at all levels," Smith said.

In the months leading up to Congress's repeal, which took effect in September, there were indications that the change might not be embraced so readily.

During a visit to a Marine combat outpost in southern Afghanistan in June, then-Defense Secretary Robert Gates was confronted by an enlisted Marine who clearly objected to the repeal. He told Gates that the Marine Corps has "a set of standards and values that is better than that of the civilian sector," and that repeal of the gay ban has "changed those values."

He asked Gates whether Marines who object to serving with gays would be allowed to opt out of their enlistment. Gates said no and predicted that if pre-repeal training was done right, "nothing will change" with regard to rules of behavior and discipline.

That Marine was not alone in making known his doubts about the wisdom of allowing gays to serve openly in uniform. In a survey of military members last year, 45 percent of Marines viewed repeal negatively in terms of how it could affect combat readiness, effectiveness and cohesion. Among those Marines who serve in combat roles, 56 percent expressed that view.

It was those statistics that caused Amos concern prior to repeal, and he made known his position in no uncertain terms when he testified to Congress last December.

"Successfully implementing repeal and assimilating openly homosexual Marines into the tightly woven fabric of our combat units has strong potential for disruption at the small unit level as it will no doubt divert leadership attention away from an almost singular focus on preparing units for combat," Amos said at the time. He stressed then and later that if repeal were approved, Marines would faithfully follow the new law.

Looking back, Amos said in the AP interview that he had no regrets about publicly opposing repeal during wartime. He said he was obliged, as the commandant of the Marines, to set aside his personal opinions and represent the views of those combat Marines who told the survey "pretty unequivocally" that repeal was problematic.

"I think I did exactly what I should have done," he said.

___

Robert Burns can be reached on Twitter at http://twitter.com/robertburnsAP

Source: http://us.rd.yahoo.com/dailynews/rss/politics/*http%3A//news.yahoo.com/s/ap/20111128/ap_on_re_mi_ea/ml_marines_gays

chili recipe chili recipe grimm

Scarlett Johansson Talks About Loving ?Bad Boys?

Scarlett Johansson Talks About Loving “Bad Boys”

Scarlett Johansson, 27, says she likes men who challenge authority and are adventurous doesn’t care how they are perceived by other people. The actress said, [...]

Scarlett Johansson Talks About Loving “Bad Boys” Stupid Celebrities Gossip Stupid Celebrities Gossip News


Source: http://feedproxy.google.com/~r/stupidcelebrities/~3/REffnhl8mws/

freedom writers lemony snicket lemony snicket jim thome jim thome fun fun fun fest fun fun fun fest